Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Tess E PetersonDivision of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA.ORCID 0000-0002-7223-651X
Virginia S HahnDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-0578-2668
Ruin MoaddelBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.
Min ZhuBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.ORCID 0000-0001-6614-606X
Jinshui FanBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.ORCID 0009-0001-9300-1920
Supriyo DeBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.ORCID 0000-0002-2075-7655
Sabina A HaberlenDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-9467-3454
Frank J PalellaDepartment of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Michael PlankeyDivision of General Internal Medicine, Department of Medicine, Georgetown University, Washington, District of Columbia, USA.ORCID 0000-0003-4554-7483
Joel S BaderDepartment of Biomedical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Joao A C LimaDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Robert E GersztenDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Jerome I RotterInstitute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.ORCID 0000-0001-7191-1723
Gregory D KirkDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-7829-1405
Damani A PiggottDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Luigi FerrucciBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.ORCID 0000-0002-6273-1613
Joseph B MargolickDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-4398-8851
Todd T BrownDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0001-8599-278X
Wendy S PostDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Katherine C WuDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-4958-5145
Funding
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
PATHOPHYSIOLOGY OF MYOCARDIAL DISEASEST32HL007227 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Chulan Kwon, WENDY S POST · 1985 to 2026
$21.2M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
CHARGE Consortium: Omics Discovery for CVD and Aging PhenotypesR01HL105756 · NHLBI · UNIVERSITY OF WASHINGTON · PI Bruce M Psaty, NICHOLAS L SMITH · 2011 to 2026
$9.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
TO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANKOW, JAMES S · 2020 to 2025
$4.4M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00003 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POST, WENDY S · 2020 to 2025
$3.8M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00007 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD · 2020 to 2025
$3.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00002 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN J · 2020 to 2025
$3.4M
Intramural Research Program of the ZIAAG000297National Heart, Lung and Blood InstituteNHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS HHSN268201500003INHLBI NIH HHS R01 HL105756NHLBI NIH HHS T32 HL007227NIAID NIH HHS K24 AI120834NIAID NIH HHS P30 AI094189NIDA NIH HHS U01 DA036297NIH HHS P30AI094189NIH HHS R01 HL126552NIH HHS U01-DA036297NIH HHS U01-HL146193NIH HHS U01-HL146201NIH HHS U01HL146201NIH HHS U01-HL146205NIH HHS U01-HL146240Sarnoff Scholar Award 138828TOPMed Data Coordinating Center 1K23HL166770-01TOPMed Data Coordinating Center 75N92025D00022TOPMed Data Coordinating Center 75N92025D00024TOPMed Data Coordinating Center 75N92025D00025TOPMed Data Coordinating Center 75N92025D00026TOPMed Data Coordinating Center 75N92025D00027TOPMed Data Coordinating Center 75N92025D00028TOPMed Data Coordinating Center DK063491TOPMed Data Coordinating Center HHSN268201800001ITOPMed Data Coordinating Center N01-HC-95159TOPMed Data Coordinating Center N01-HC-95160TOPMed Data Coordinating Center N01-HC-95161TOPMed Data Coordinating Center N01-HC-95162TOPMed Data Coordinating Center N01-HC-95163TOPMed Data Coordinating Center N01-HC-95164TOPMed Data Coordinating Center N01-HC-95165TOPMed Data Coordinating Center N01-HC-95166TOPMed Data Coordinating Center N01-HC-95167TOPMed Data Coordinating Center N01-HC-95168TOPMed Data Coordinating Center N01-HC-95169TOPMed Data Coordinating Center R01HL105756TOPMed Data Coordinating Center R01HL-120393TOPMed Data Coordinating Center U01HL-120393TOPMed Data Coordinating Center UL1-TR-000040TOPMed Data Coordinating Center UL1-TR-001079TOPMed Data Coordinating Center UL1-TR-001420TOPMed Data Coordinating Center UL1TR001881TOPMed Informatics Research Center 3R01HL-117626-02S1TOPMed Informatics Research Center HHSN268201800002I
6 · The paper itself
Abstract
backgroundPeople with human immunodeficiency virus (HIV) (PWH) are at higher risk of myocardial fibrosis and subsequent heart failure (HF) compared to people without HIV (PWOH). Mechanisms underlying this risk and its specificity to PWH are unclear.
methodsWe measured 2594 proteins in plasma obtained concurrently with cardiovascular magnetic resonance imaging among 342 PWH and PWOH. We estimated associations with HIV serostatus and myocardial fibrosis (elevated extracellular volume fraction [ECV] ≥30% among women, ≥28% among men) using multivariable regression. Among an independent community-based cohort, we estimated associations between the identified signature and time to incident HF.
resultsMean age of participants was 55 (standard deviation [SD], 6) years, 25% were female, 61% were PWH (88% on antiretroviral therapy, 74% with undetectable HIV RNA), and 52% had elevated ECV. We identified 39 proteins and 1 cluster of 42 proteins that were higher among PWH versus PWOH and positively associated with elevated ECV, independent of risk factors (false discovery rate <0.05). Among an independent cohort of 3223 PWOH (mean age, 68 [SD, 9] years; 52% female; 118 incident HF cases over a mean of 9.8 [SD, 1.4] years), we found that this protein cluster and 34 of 39 individual proteins were associated with time to incident HF. This signature was statistically enriched for T-cell activation, tumor necrosis factor signaling, ephrin signaling, and tissue maintenance and repair.
conclusionsWe identified an HIV-related proteomic signature associated with myocardial fibrosis regardless of HIV serostatus and that predicted incident HF among the general population. Our results identify several novel associations related to specific immune processes that may contribute to risk of myocardial fibrosis and subsequent HF among both PWH and PWOH.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Human Immunodeficiency Virus-Associated Proteomic Signature of Myocardial Fibrosis and Incident Heart Failure. · full record | Socratic